{"name":"Jubilant Pharmova","slug":"jubilant","ticker":"JUBLPHARMA.NS","exchange":"NSE","domain":"jubilantpharmova.com","description":"Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distr","hq":"Noida, Uttar Pradesh, India","founded":1997,"employees":"5547","ceo":"Shyam S. Bhartia (Chairman) / Hari S. Bhartia (Co-Chairman)","sector":"CDMO / Radiopharmaceuticals / Generics","stockPrice":877.7,"stockChange":8.3,"stockChangePercent":0.95,"marketCap":"$139.1B","metrics":{"revenue":79184003072,"revenueGrowth":16.5,"grossMargin":64.9,"rdSpend":0,"netIncome":4327000064,"cash":6232000000,"dividendYield":0.59,"peRatio":32.3,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2016-01-01","label":"Rubidium Bromatum first approved","drug":"Rubidium Bromatum","drugSlug":"rubidium","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Lorazepam patent cliff ($10.8M at risk)","drug":"Lorazepam","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Doxorubicin Hydrochloride patent cliff ($12.4M at risk)","drug":"Doxorubicin Hydrochloride","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Rubidium Bromatum","genericName":"RUBIDIUM","slug":"rubidium","indication":"Positron emission tomography","status":"marketed"}]}],"pipeline":[{"name":"Rubidium Bromatum","genericName":"RUBIDIUM","slug":"rubidium","phase":"marketed","mechanism":"Small molecule","indications":["Positron emission tomography"],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"earnings","headline":"Jubilant Pharmova Reports Q3 FY2024 Earnings","summary":"Jubilant Pharmova reported its Q3 FY2024 earnings, with revenue of ₹1,444.4 crore and a net profit of ₹144.4 crore.","drugName":"","sentiment":"neutral"},{"date":"2023-08-22","type":"deal","headline":"Jubilant Pharmova Partners with AstraZeneca for Radiopharmaceutical Manufacturing","summary":"Jubilant Pharmova has partnered with AstraZeneca to manufacture radiopharmaceuticals for the latter's pipeline products.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTFBRNXQ2VTV4V0xfMExxSk9iV1IwamUwb01UWmllNkVmU2U1eV9oVHRJTUg5VDFMb3Btei1BbEJONk9DV1BocVM4dFZnb1R0em9MWndBVDFINUV5RzI2dkNiMVUxWnU4WDQ?oc=5","date":"2024-08-28","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Innova Captab Limited (INNOVACAP.NS) company profile and facts - Yahoo Finance Singapore","headline":"Innova Captab Limited (INNOVACAP.NS) company profile and facts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE1OVWxWeC10MXBfYzNScDdERnh4MFRQbjV3UF9ULTdISkNja2RVTXUyd3R2c2g3anVpSTk5WGlRZzV4cnVJaFZHY2xMbVBYUTNud19kVG9ZNjR0REFScWc?oc=5","date":"2021-05-31","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Jubilant Pharmova Limited (JUBLPHARMA.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Jubilant Pharmova Limited (JUBLPHARMA.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE13Y2Q0bXdqQXdrTXZuUlZEbWVkZTlfdjV2SlY0dkJGaURISDZGakUtYzFxakhDWEJNTUVkOE1WaFNRNTJvSVoydS16TDJ5cWRUWHNCSDZFZUF1ZjRHTEE?oc=5","date":"2018-07-18","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Neuland Laboratories Limited (NEULANDLAB.NS) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Neuland Laboratories Limited (NEULANDLAB.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE52Rmh5MGJHY1BQSm92dG9xSDFoQ0xXQ3diekY5Q054YjEwQUlfWEFOOVFXaXB2cFV3UEF2dGI1UzJRcl9NUllwdFMyYVFLWjZOYnBZUlUwNE1ZSE1kSlE?oc=5","date":"2017-06-15","type":"pipeline","source":"Yahoo Finance Australia","summary":"Aurobindo Pharma Limited (AUROPHARMA.NS) stock price, news, quote and history - Yahoo Finance Australia","headline":"Aurobindo Pharma Limited (AUROPHARMA.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE94dTB2bUlQRGp3bWlkS0dmN1VwVXI4OXpFaVdyUTNxaHc5TEtMSjFVM1R5clpPRmZHRXA0OTRFX2EyaHlwOENiUzlzdWJQR3Z6eDIyX1VydkNIdw?oc=5","date":"2017-06-07","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Ipca Laboratories Limited (IPCALAB.NS) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Ipca Laboratories Limited (IPCALAB.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE81M09rdXk0VGNvb09nU053X0Y2ZS1hcGdSOU80dk9vZzVqLUFNc2ZfX3ZwZzUxMGV4aU83ZXVINmhudkNOZXJxbHhtbjdPMTg2aVkwYzExWE9XOEo1?oc=5","date":"2017-05-20","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Shilpa Medicare Limited (SHILPAMED.NS) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Shilpa Medicare Limited (SHILPAMED.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE1kX0ZKRjUxVkM1SWNEMDRsNUpURTIyYXBtU3FRN0lTT2ZORTdWMVdDTTFqaTZaWnd6MWhWTkFtb1ZGYkFYV2VIMnR3LU1HMGdRRmprbmlRcUNDUQ?oc=5","date":"2017-05-20","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Nectar Lifesciences Limited (NECLIFE.NS) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Nectar Lifesciences Limited (NECLIFE.NS) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Lorazepam","drugSlug":"lorazepam","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":10800000},{"drugName":"Doxorubicin Hydrochloride","drugSlug":"doxorubicin-hydrochloride","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":12400000}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Catalent","Piramal Pharma Solutions","Aptuit"],"therapeuticFocus":["Radiopharmaceuticals","Generics"],"financials":null,"yahoo":{"currentPrice":877.7,"previousClose":869.4,"fiftyTwoWeekHigh":1248,"fiftyTwoWeekLow":786.05,"fiftyTwoWeekRange":"786.05 - 1248.0","fiftyDayAverage":882.95,"twoHundredDayAverage":1048.78,"beta":0.48,"enterpriseValue":160464650240,"forwardPE":24.2,"priceToBook":2.11,"priceToSales":1.76,"enterpriseToRevenue":2.03,"enterpriseToEbitda":14.99,"pegRatio":0,"ebitda":10702749696,"ebitdaMargin":13.5,"freeCashflow":0,"operatingCashflow":0,"totalDebt":28828000256,"debtToEquity":43.9,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":2,"targetMeanPrice":1312.5,"targetHighPrice":1325,"targetLowPrice":1300,"dividendRate":5,"payoutRatio":0.18,"fiveYearAvgDividendYield":0.7,"exDividendDate":1753401600,"insiderHeldPercent":58,"institutionHeldPercent":21.2,"sharesOutstanding":158369748,"floatShares":63525903,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":27.21,"epsForward":36.3,"revenuePerShare":499.52,"bookValue":415.87,"officers":[{"age":49,"name":"Mr. Priyavrat  Bhartia MBA","title":"MD & Director"},{"age":38,"name":"Mr. Arjun Shanker Bhartia","title":"Joint MD & Director"},{"age":59,"name":"Mr. Arun Kumar Sharma B.Sc., C.A.","title":"CFO & Group Treasurer"},{"age":61,"name":"Mr. Prakash Chandra Bisht B.Com., CA","title":"Executive VP of Group Accounts"},{"age":59,"name":"Mr. Sanjay  Gupta A.C.M.A., B.Com., L.L.B.","title":"Executive VP & Head of Legal"},{"age":51,"name":"Mr. Naresh  Kapoor","title":"Company Secretary & Compliance Officer"},{"age":null,"name":"Mr. Shantanu  Jha","title":"Group Chief Human Resources Officer"},{"age":66,"name":"Mr. Rajagopal  Sankaraiah B.Sc., CA, F.C.A.","title":"Advisor"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.jubilantpharmova.com","phone":"91 12 0436 1000"}}